| NCT ID | NCT00162474 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hadassah Medical Organization |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2003-09 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2003-09 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin. The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
Eligibility Criteria
Inclusion Criteria: * Age range of 20-50 years old * The absence of significant disease states Exclusion Criteria: * Known hypersensitivity to warfarin or phenytoin * Known hepersensitivity to penicillins or cephalosporins (Dicloxacillin part) * The presence of significant disease states * Regular use of drugs (including birth control pills)
Contact & Investigator
Yoseph Caraco, MD
PRINCIPAL INVESTIGATOR
Hadassah Medical Organization
Frequently Asked Questions
Who can join the NCT00162474 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00162474 currently recruiting?
Yes, NCT00162474 is actively recruiting participants. Contact the research team at caraco.yoseph@mail.huji.ac.il for enrollment information.
Where is the NCT00162474 trial being conducted?
This trial is being conducted at Jerusalem, Israel.
Who is sponsoring the NCT00162474 clinical trial?
NCT00162474 is sponsored by Hadassah Medical Organization. The principal investigator is Yoseph Caraco, MD at Hadassah Medical Organization. The trial plans to enroll 1,000 participants.